SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medicamen Organics Ltd (MEDIORG)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: MEDIORG Pharmaceuticals & Drugs | Small Cap | Medicamen Organics Share Price

BSE Share Price
Not Listed

Medicamen Organics Ltd (MEDIORG)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: MEDIORG Pharmaceuticals & Drugs | Small Cap | Medicamen Organics Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹30 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹-2.5
TTM Sales
₹21.7 Cr.
Book Value per Share
₹24.2
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
49.2
Price to Book (P/B)
1.03
Lower than its 5-year historical median
Price to Sales (P/S)
1.40
Higher than its 5-year historical median
EV/EBITDA
-14.48
Lower than its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
14.79%
Outperforms industry median
Return on Capital Employed (ROCE)
14.13%
Outperforms industry median
Return on Assets (ROA)
6.82%
Operating Profit Margin
15.1%
Net Profit Margin
8.82%
Gross Profit Margin
13.8%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
46.77%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
17.51%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
24.81%
Asset Quality
Promoter Holding
59.73%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹17 Cr.
Equity
₹12.2 Cr.
Face Value
₹10
All Time Low / High
- / -

Medicamen Organics stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Medicamen Organics Ltd a good quality company?
Medicamen Organics Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Medicamen Organics Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Medicamen Organics Ltd vs industry peers?
Medicamen Organics Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Medicamen Organics Ltd?
Promoters hold 59.73% of the Medicamen Organics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Medicamen Organics Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -9.55% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Medicamen Organics Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 5.7%4.1%10.1%20.9%14.1%-
Value Creation
Index
-0.6-0.7-0.30.50.0-

Growth Parameters

Sales 25.12122.225.337.122
Sales YoY Gr.--16.3%5.6%14.1%46.8%-
Adj EPS 0.50.21.63.12.8-2.5
YoY Gr.--66%858.8%87.1%-8.2%-
BVPS (₹) 12.513.41517.724.824.2
Adj Net
Profit
0.30.112.63.3-3
Cash Flow from Ops. -1.20-0.6-3.7-4.9-
Debt/CF from Ops. -8.2274-20.2-3.5-2.5-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANA20.9%46.8%
Adj EPS NANA154.4%-8.2%
BVPSNANA22.9%39.6%
Share Price - - - -39.9%

Key Financial Parameters

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
41.311.521.614.6-10.2
Op. Profit
Mgn %
6.55.78.518.815.1NAN
Net Profit
Mgn %
1.20.54.410.48.9-14.1
Debt to
Equity
1.31.31.30.80.4-
Working Cap
Days
02603053513390
Cash Conv.
Cycle
053801501590

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales25.0520.9822.1525.2737.09
Operating Expenses + 23.4119.7820.2820.5331.52
Manufacturing Costs6.1610.025.846.7012.91
Material Costs12.605.649.969.1711.97
Employee Cost 2.332.492.872.993.23
Other Costs 2.321.631.611.683.40
Operating Profit 1.631.201.874.745.57
Operating Profit Margin (%) 6.5%5.7%8.4%18.7%15.0%
Other Income + 0.010.210.821.070.10
Exceptional Items 00000
Interest 0.480.470.610.650.54
Depreciation 0.680.680.710.720.74
Profit Before Tax 0.490.261.364.444.39
Tax 0.190.150.391.811.12
Profit After Tax 0.300.100.972.623.27
PAT Margin (%) 1.2%0.5%4.4%10.4%8.8%
Adjusted EPS (₹)0.50.21.63.12.8
Dividend Payout Ratio (%)0%0%0%0%0%

Valuation of Medicamen Organics - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 7.478.018.9815.2628.97
Share Capital 6668.6011.70
Reserves 1.472.012.986.6617.27
Debt +9.069.8211.4812.4911.99
Long Term Debt0.640.640.330.160.16
Short Term Debt8.429.1811.1512.3311.83
Minority Interest00000
Trade Payables7.027.3197.0811.67
Others Liabilities 2.802.393.133.614.81
Total Liabilities 26.3427.5432.5938.4457.44

Fixed Assets

Net Fixed Assets +11.3511.2910.8710.3510.13
Gross Block15.8416.4616.741818.37
Accumulated Depreciation4.485.165.887.658.24
CWIP 0000.152.22
Investments 00000.27
Inventories2.664.726.146.147.49
Trade Receivables7.536.2510.7716.7024.75
Cash Equivalents 0.880.440.530.553.27
Others Assets 3.924.844.284.559.32
Total Assets 26.3427.5432.5938.4457.44

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + -1.160.04-0.58-3.66-4.91
PBT 0.490.261.363.394.39
Adjustment 1.5710.531.351.02
Changes in Working Capital -3.18-1.15-2.43-8.22-10.22
Tax Paid -0.05-0.07-0.05-0.18-0.09
Cash Flow From Investing Activity + -0.02-0.59-0.28-0.34-2.62
Capex -0.03-0.62-0.29-0.35-2.45
Net Investments 00000
Others 0.010.020.010.01-0.18
Cash Flow From Financing Activity + 1.270.180.944.0110.25
Net Proceeds from Shares 0003.8010.54
Net Proceeds from Borrowing 00-0.31-0.39-0
Interest Paid -0.48-0.47-0.61-0.65-0.51
Dividend Paid 00000
Others 1.750.651.861.250.23
Net Cash Flow 0.09-0.370.070.022.72

Financial Ratio

PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)3.991.3111.4121.6514.79
ROCE (%)5.674.1310.1120.8814.13
Asset Turnover Ratio0.950.780.740.710.77
PAT to CFO Conversion(x)-3.870.4-0.6-1.4-1.5
Working Capital Days
Receivable Days109.70119.90140.20198.40204
Inventory Days38.8064.2089.5088.7067.10
Payable Days203.20463.20298.90320285.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Medicamen Organics Ltd FAQs

The current trading price of Medicamen Organics on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Medicamen Organics stood at ₹30.41 Cr

The latest P/E ratio of Medicamen Organics as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Medicamen Organics as of 31-Dec-1969 is 1.03.

The 52-week high of Medicamen Organics is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Medicamen Organics is ₹21.65 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Medicamen Organics Ltd is a below average quality company.

The key valuation ratios of Medicamen Organics Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Medicamen Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Medicamen Organics Ltd

Medicamen Organics Limited was incorporated on March 15, 1995 as ‘Panchdeep Pharmaceuticals Limited’, a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. The company has received Certificate of Commencement of Business on March 15, 1995, issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of the Company was changed to ‘Medicamen Organics Limited’ and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi.

Medicamen Organics is engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer. It markets its product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis. Its products are marketed across India as well as African, CIS and south East Asian Countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by its third-party distributor.

Its manufacturing facilities are capable of producing pharmaceutical formulations and products and has fully equipped quality control department with experienced and qualified staff to facilitate smooth manufacturing process. It has in-house testing laboratory and necessary infrastructure to test its raw materials and finished products to match the quality standards. Its core strength lies in product development and documentation, it is regularly engaged in research and development and launching new products. This gives it an exhaustive product list as well as fair pricing in the market. Its product portfolio consists of comprises of wide range of drugs like, Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Proton Pump Inhibitor, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral and Nonsteroidal anti-inflammatory drug (NSAIDS).

Business area of the company

The company is engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer.

Products category

  • Capsules
  • Ointment/external preparation
  • Suspension
  • Dry powder sachet
  • Tablet

Awards and accreditations

  • 2015: ISO 9001:2015 - Manufacture and Supply of Food Supplement for Human use and Non Beta Lactum Tablets, Capsules, Liquid and Ointments (Unit II). 
  • 2015: ISO 9001: 2008 Manufacture and Supply of Food Supplement for Human Use (Unit II). 
  • 2010: ISO 9001: 2008 (Quality Management System). 
  • 2018. ISO 9001:2015 certified company (Unit I) Manufacture and Supply of Tablets, Capsules and Liquid Orals for both Domestic and Export Market.

History and milestones

  • 1995: The company was incorporated as a Public Limited company under the name ‘Panchdeep Pharmaceuticals Limited’ and later the company has changed its name from ‘Panchdeep Pharmaceuticals Limited’ to ‘Medicamen Organics Limited’.
  • 1996: It started with trading of pharmaceuticals for supplies to various Government departments.
  • 1998-2007: It took loan license with ‘M/s Rhydurg Pharmaceuticals’, a unit situated in Kundali across the border of Delhi and started getting product manufactured for its marketing.
  • 2007: It purchased a plot of land measuring 1200 square meter from SIDCUL Industrial Authority in Haridwar and started construction for its own pharma unit. The construction of three-storeyed building (including basement measuring 15000 sq. feet was completed and it got its own manufacturing license for tablets, capsules, oral liquids in form 25 and 28 and started its owns production in the same year (UNIT-I).
  • 2007: It received WHO/GMP Certificate for Unit I.
  • 2010: It applied for a license for manufacturing of food supplements, like protein powders, vitamin tablets and syrups etc. and got its first license.
  • 2017: It received WHO/GMP Certificate for Unit I.
  • 2017: It got an opportunity to purchase one readymade adjacent unit to shift its food production in a separate unit. It got its first license in this Unit and tied up with renowned Pharma company for one of their renowned products for manufacturing in its plant. This unit was termed as (UNIT-II).
  • 2017: It stopped production of general pharma products in Unit-I and converted it into a unit for exclusive production of Iron Tablets because of its huge world-wide demand.

You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: